Financial Survey: CAMP4 Therapeutics (NASDAQ:CAMP) vs. Citius Oncology (NASDAQ:CTOR)

CAMP4 Therapeutics (NASDAQ:CAMP) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of current recommendations for CAMP4 Therapeutics and Citius Oncology, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CAMP4 Therapeutics	1	1	5	0	2.57
Citius Oncology	1	0	2	0	2.33

CAMP4 Therapeutics currently has a consensus price target of $8.60, suggesting a potential upside of 109.25%. Citius Oncology has a consensus price target of $6.00, suggesting a potential upside of 669.23%. Given Citius Oncology’s higher probable upside, analysts clearly believe Citius Oncology is more favorable than CAMP4 Therapeutics.

Earnings & Valuation

This table compares CAMP4 Therapeutics and Citius Oncology”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CAMP4 Therapeutics	$3.50 million	60.98	-$80.40 million	($2.36)	-1.74
Citius Oncology	N/A	N/A	-$24.76 million	($0.47)	-1.66

Citius Oncology has lower revenue, but higher earnings than CAMP4 Therapeutics. CAMP4 Therapeutics is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

70.5% of Citius Oncology shares are held by institutional investors. 21.7% of CAMP4 Therapeutics shares are held by company insiders. Comparatively, 7.8% of Citius Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

CAMP4 Therapeutics has a beta of 0.08, indicating that its share price is 92% less volatile than the S&P 500. Comparatively, Citius Oncology has a beta of 3.41, indicating that its share price is 241% more volatile than the S&P 500.

Profitability

This table compares CAMP4 Therapeutics and Citius Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CAMP4 Therapeutics	-2,193.72%	-194.74%	-95.64%
Citius Oncology	N/A	-99.47%	-42.16%

Summary

Citius Oncology beats CAMP4 Therapeutics on 9 of the 13 factors compared between the two stocks.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location. The company also offers telematics products, including asset tracking units, mobile telematics devices, fixed and mobile wireless gateways, and routers; and advanced telematics products for the broader connected vehicle and Internet of Things marketplace, which enable customers to optimize their operations by collecting, monitoring, and reporting business-critical information and desired intelligence from remote and mobile assets. In addition, it offers professional services, including project management, engineering services, and installation services. The company sells its products and services to customers in the automotive, telecommunications, industrial equipment, transportation and logistics, government and municipalities, insurance, original equipment manufacturers, and leasing companies. It markets through direct sales organization, channel partner program, original equipment manufacturers, and independent sales representatives and distributors, as well as its websites and digital platform. The company was incorporated in 1981 and is headquartered in Irvine, California.

About Citius Oncology

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.